A synopsis of individual key papers that evidence improved patient outcomes and increased economic benefit with a TAVI procedure vs alternative pathways, taking into account organisational efficiency, budget considerations, patient choice and how to implement change in your organisation.
‘Valve for Life’: tackling the deficit in transcatheter treatment of heart valve disease in the UK
Authors: Ali N, Faour A, Rawlins J, Dawkins S, et al..
Citation: Open Hear 2021;8: e001547
DOI: 10.1136/openhrt-2020-001547
Period of study: –
Facilitating transcatheter aortic valve implantation in the era of COVID-19: Recommendations for programmes
Authors: Lauck S, Forman J, Borregaard B, Sathananthan J, et al.
Citation: Eur J Cardiovasc Nursing. 2020;19:537–44.
doi:10.1177/1474515120934057.
Period of study: –
The cost-effectiveness of TAVR in low surgical risk patients with severe aortic stenosis
Authors: Tam DY, Azizi PM, Fremes SE, Chikwe J, et al.
Citation: Eur Heart J Qual Care Clin Outcomes. 2020 Jul 9;qcaa058. DOI: 10.1093/ehjqcco/qcaa058.
Period of study: –
SCAI/ACVP expert consensus statement on cardiovascular catheterization laboratory economics
Authors: Blankenship JC, Choi JW, Das TS, McElgunn PM, et al.
Citation: Catheter Cardiovasc Interv. 2019; 94: 123–35
DOI:10.1002/ccd.28330.
Patient enrolment: May 2015 – October 2017
Effective Operational Management in the Cardiac Catheterization Laboratory (Review paper)
Authors: Reed GW, Tushman ML, Kapadia SR, et al.
Citation: J Am Coll Cardiol. 2018;72:2507–17
DOI:10.1016/j.jacc.2018.08.2179.
Period of study: –
Health Status after Transcatheter vs Surgical Aortic Valve Replacement in Low-risk Patients with Aortic Stenosis
Authors: Baron SJ, Magnuson EA, Lu M, Wang K, et al.
Citation: J Am Coll Cardiol. 2019;74:2833–42
DOI:10.1016/j.jacc.2019.09.007.
Period of study: March 2016 and October 2019
Transcatheter Aortic-Valve Replacement with a Balloon Expandable Valve in Low-Risk Patients
Authors: Mack MJ, Leon MD, Thourani VH, Makkar R, et al. for the PARTNER 3 Investigators
Citation: N Engl J Med. 2019;380:1695–1705
DOI: 10.1056/NEJMoal1814052.
Period of study: March 2016 – October 2017
Thirty-day readmission after TAVR in the United States: Insights from the Nationwide Readmission Database
Authors: Kolte D, Khere S, Sardar MR, Gheewala N, et al.
Citation: Circ Cardiovasc Interv. 2017;10:e004472
DOI:10.1161/CIRCINTERVENTIONS.116.00472.
Period of study: January to November 2013
TAVR versus surgical valve replacement in intermediate-risk patients: A propensity score analysis
Authors: Thourani VH, Kodali S, Makkar RR, Hermann HC, et al.
Citation: Lancet. 2016;387:2218–25
DOI:10.1016/S0140-6736(16)30073-3.
Period of study: December 2011 – November 2013
Length of stay after transfemoral TAVR: an analysis of the STS/ACC TVT Registry
Authors: Wayangankar SA, Elgendy IY, Xiang Q, Jneid H, et al.
Citation: JACC Cardiovasc Interv. 2019;12:422-430.
doi:0.1016/j.jcin.2018.11.015.
Period of study: November 2011 to September 2015
Comparison of local versus general anesthesia in patients undergoing TAVR: A meta-analysis
Authors: Villablanca P.A, Mohananey D, Nikolic K, Bangalore S, et al.
Citation: Catheter Cardiovasc Interv. 2018;91:330–42
DOI: 10.1002/ccd.27207.
Period of study: Meta-analysis of studies 2008–2016
Vancouver TAVR Clinical Pathway. Min. Approach, Standardized Care, and Discharge Criteria to Reduce LoS
Authors: Lauck SB, Wood DA, Baumbusch J, Kwon J-Y, et al.
Citation: Circ Cardiovasc Qual Outcomes. 2016;9:312–21. DOI:10.1161/CIRCOUTCOMES.115.002541.
Period of study: May 2012 to October 2014
Optimising patient discharge management after transfemoral TAVI: The European FAST-TAVI trial
Authors: Barbanti M, van Mourik MS, Spence MS, Iacovelli F, et al.
Citation: EuroIntervention. 2019;15:147–54
DOI:10.4244/EIJ-D-18-01197.
Patient enrolment: May 2015 – October 2017
The Vancouver 3M Clinical Pathway Facilitates Safe Next-Day Discharge Home
Authors: Wood DA, Lauck SB, Cairns JA, Humphriees KH, et al.
Citation: JACC Cardiovasc Interv. 2019;12:459–68
DOI:10.1016/j.jcin.2018.12.0020.
Period of study: March 2015 and April 2017
Annual Number of Candidates for TAVI Per Country: Current Estimates and Future Projections
Authors: Durko AP, Osnabrugge RL, Van Mieghem NM, Milojevic M, et al.
Citation: Eur Heart J. 2018 Jul 21;39(28):2635-2642.
doi: 10.1093/eurheartj/ehy107.
Period of study: January 2017
Summarising the evidence for improved patient outcomes and increased economic benefit with a TAVI procedure vs alternative pathways, taking into account organisational efficiency, budget considerations, patient choice and how to implement change in your organisation.
EuroPCR highlights (18-20 May) Part 3: The Edwards Benchmark™ program
Highlights from EuroPCR 2021 focus on TAVI for aortic stenosis: presentations include TAVI in a before-now excluded patient population, bicuspid aortic stenosis and on the contemporary challenges for TAVI such as expanding patient populations, valve durability and long-term outcome data…
EuroPCR highlights (18-20 May) Part 2: Optimising the TAVI procedure
Highlights from EuroPCR 2021 focus on TAVI for aortic stenosis: presentations include TAVI in a before-now excluded patient population, bicuspid aortic stenosis and on the contemporary challenges for TAVI such as expanding patient populations, valve durability and long-term outcome data…
EuroPCR highlights Part 1: Evolving eligible patient population for TAVI (18-20 May 2021)
Highlights from EuroPCR 2021 focus on TAVI for aortic stenosis: presentations include TAVI in a before-now excluded patient population, bicuspid aortic stenosis and on the contemporary challenges for TAVI such as expanding patient populations, valve durability and long-term outcome data…
Improving care pathways: Permanent Pacemaker Insertion after TAVI
TAVI pathways need to be mapped out with PPI built into the patient journey with a consistent approach that optimises patient outcomes and service efficiency.
Management of severe symptomatic aortic stenosis in the age of COVID-19: A key paper summary
Read the key paper summary showing TAVI as the treatment of choice for all-risk ssAS patients carries even greater benefits during and post-COVID-19.
This content is sponsored by Edwards Lifesciences
Ⓒ Cogora 2021
Cogora Limited, 140 London Wall, London EC2Y 5DN, Registered in the United Kingdom. Reg. No. 2147432
